sofosbuvir-velpatasvir
Selected indexed studies
- Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. (Expert Rev Gastroenterol Hepatol, 2021) [PMID:34338120]
- Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C. (Aust Prescr, 2019) [PMID:31363313]
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. (Drugs, 2018) [PMID:29546556]
_Worker-drafted node — pending editorial review._
Connections
sofosbuvir-velpatasvir is a side effect of
Sources
- Sofosbuvir/velpatasvir for the treatment of hepatitis C in pediatric patients. (2021) pubmed
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C. (2018) pubmed
- Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C. (2018) pubmed
- Safety and efficacy of sofosbuvir-velpatasvir: A meta-analysis. (2022) pubmed
- Sofosbuvir/Velpatasvir: A Review in Chronic Hepatitis C. (2016) pubmed
- Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C. (2017) pubmed
- Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C. (2019) pubmed
- Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C. (2019) pubmed
- Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection. (2021) pubmed
- Sofosbuvir and velpatasvir for the treatment of hepatitis C. (2017) pubmed